Q - Ceribell,
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
| Name | Action | Date | Trading Arrangement | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Josef Parvizi, M.D., Ph.D.Director, Chief Medical Advisor, and Co-Founder | Adopt | May 22, 2025 | X | 180,000 | April 30, 2026 |
| Josef Parvizi, M.D., Ph.D.Director, Chief Medical Advisor, and Co-Founder | Terminate(1) | June 25, 2025 | X | 180,000 | April 30, 2026 |
| Raymond Woo, Ph.D.Chief Technology Officer | Adopt | May 28, 2025 | X | 120,008 | May 19, 2026 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
(1)Dr. Parvizi's trading plan, originally adopted on May 22, 2025, wasterminated on June 25, 2025 due to a clerical error in the drafting of the plan. No trades were executed under the plan prior to its termination.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.